High-dose chemotherapy followed by autologous bone marrow transplantation in relapse of medulloblastoma;Chimiotherapie intensive des rechutes du medulloblastome du jeune enfant

Bulletin du Cancer

Volumn 84, Issue 3, 1997, Pages 264-272

  Dupuis Girod, Sophie ^a   Hartmann, Olivier ^a   Benhamou, Ellen ^a   Doz, François ^b   Mechinaud, Françoise ^c   Bouffet, Eric ^d   Coze, Carole ^e   Kalifa, Chantal ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT CURIE   (France)

^c Service d'Oncologie Pédiatrique   (France)

^d CENTRE LÉON BÉRARD   (France)

^e TIMONE HOSPITAL   (France)

Author keywords

bone marrow transplantation; busulfan; children; medulloblastoma; thiotepa

Indexed keywords

BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IFOSFAMIDE; PROCARBAZINE; THIOTEPA; VINCRISTINE; ANTINEOPLASTIC AGENT;

ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; HUMAN; INFANT; MEDULLOBLASTOMA; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CEREBELLUM TUMOR; DRUG ADMINISTRATION; FEMALE; MALE; MORTALITY; MULTIMODALITY CANCER THERAPY; PRESCHOOL CHILD; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BUSULFAN; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; MALE; MEDULLOBLASTOMA; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE; THIOTEPA; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0031089078     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Baram T, Eys J, Dowell R, et al. Survival and neurologic outcome of infants with medulloblastoma treated with surgery and MOPP chemotherapy. Cancer 1987; 60: 173-7.
2. Bouffet E, Bernard J, Frappaz D, et al. M4 protocol for cerebellar medulloblastoma: supratentorial radiotherapy may not be avoided. Int J Radiat Oncol Biol Phys 1992; 24: 79-85.
3. Cangir A, Ragab A, Steuber P, et al. Combination chemotherapy with vincristine, procarbazine, prednisone with or without nitrogen mustard (MOPP vs OPP) in children with recurrent brain tumors. Med Pediatr Oncol 1984; 12: 1-3.
4. Chin H, Maruyama Y. Age at treatment and long-term performance results in medulloblastoma. Cancer 1984; 53: 1952-8.
5. Cohen B, Packer R, Siegel K, et al. Brain tumours in children under two years: treatment, survival and long-term prognosis. Pediatr Neurosurg 1994; 19: 171-9.
6. Conti Reed U, Rosemberg S, Gherpelli J, et al. Brain tumour in the first two years of life: a review of forty cases. Pediatr Neurosurg 1993; 19: 180-5
7. Danoff B, Cowchock S, Marquette C, et al. Assessment of the long-term effects of primary radiation therapy for brain tumors in children. Cancer 1982; 49: 1580-6.
8. Duffner P, Cohen M, Thomas P. Late effects of treatment on the intelligence of children with posterior fossa tumors. Cancer 1983; 51: 233-7.
9. Duffner P, Horowitz M, Krischer J, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. New Engl J Med 1993; 328: 1725-31.
10. Evans A, Jenkin D, Sposto R, et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 1990; 72: 572-82.
11. Finlay J, August C, Packer R, et al. High-dose multi-agent chemotherapy followed by bone marrow rescue for malignant astrocytomas of childhood and adolescence. J Neur Oncol 1990; 9: 239-48.
12. Garcia Perez A, Sierrasumaga L, Narbona Garcia J, et al. Neuropsychological evaluation of children with intracranial tumours: impact of treatment modalities. Med Pediatr Oncol 1994; 23: 116-23.
13. Hartmann O, Pein F, Beaujean F, et al. High-dose polychemotherapy with autologous bone marrow transplantation in children with relapsed lymphomas. J Clin Oncol 1984; 2: 979-86.
14. Hartmann O, Benhamou E, Beaujean F, et al. High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: a phase II study. J Clin Oncol 1986; 4: 1804-10.
15. Hassan M, Oberg G, Ehrsson H, et al. Phamacokinetics and metabolics studies of high-dose busulfan in adults. Eur J Clin Pharmacol 1989; 36: 525-30.
16. Heidemann R, Cole D, Balis F, et al. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose dependent plasma clearance of thiotepa. Cancer Res 1989a; 49: 736-41.
17. Heidemann R, Packer R, Albright L, Freeman C, Rorke L. Tumor of central nervous system. In: Pizzo, ed. Principles and practice of pediatric oncology. 2nd ed. Philadelphia: Lippincott, 1989b; 633-90.
18. Horowitz M, Mulhern R, Kun L, et al. Brain tumors in the very young child. Postoperative chemotherapy in combined-modality treatment. Cancer 1988; 61: 428-34.
19. Jannoun L, Bloom H. Long-term psychological effects in children treated for intracranial tumors. Int J Radiat Oncol Biol Phys 1989; 18: 747-53.
20. Kalifa C, Hartmann O, Demeocq F, et al. High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study. Bone marrow Transplant 1992; 9: 227-33.
21. Kovnar E, Kellie S, Horowitz M, et al. Preradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a phase II study. J Clin Oncol 1990; 8: 330-6.
22. Kumar R, Tekkok I, Jones R. Intracranial tumors in the first 18 months of life. Child's Nerv Syst 1990; 6: 371-4.
23. Kun L, Constine L. Medulloblastoma, caution regarding new treatment approaches. Int J Radiat Oncol Biol Phys 1991; 20: 897-9.
24. Meadows A, Massari D, Fergusson J, et al. Declines in IQ scores and cognitive dysfunctions in children with acute lymphocytic leukemia treated with cranial irradiation. Lancet 1981; 7: 1015-8.
25. Mosijczuk A, Nigro M, Thomas P, et al. Preradiation chemotherapy in advanced medulloblastoma. Cancer 1993; 72: 2755-62.
26. Mulhern R, Kun L. Neuropsychologic function in children with brain tumors. Interval changes in the six months following treatment. Med Pediatr Oncol 1985; 13: 318-24.
27. Nishiyama K, Funakoshi S, Izumoto S, et al. Long-term effects of radiation for medulloblastoma on intellectual and physical development. A case report of monozygotic twins. Cancer 1993; 73: 2450-5.
28. Oshan J, Gubernick J, Packer R, et al. The effects of adjuvant chemotherapy on growth in children with medulloblastoma. Cancer 1992; 70: 2013-7.
29. Packer R, Sutton L, Atkins T, et al. A prospective study of cognitive function in children receiving whole-brain radiotherapy and chemotherapy: two-year results. J Neurosurg 1989; 70: 707-13.
30. Packer R, Sutton L, Goldwein J, et al. Improved survival with the use of adjuvant chemotherapy in treatment of medulloblastoma. J Neurosurg 1991; 74: 433-40.
31. Pendergrass T, Milstein J, Geyer J, et al. Eight-drugs-in-one-day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy. J Clin Oncol 1987; 5: 1221-31.
32. Seaver E, Geyer R, Sulzbacher S, et al. Psychological adjustment in long-term survivors of childhood medulloblastoma and ependymoma treated with craniospinal irradiation. Pediatr Neurosurg 1994, 20: 248-53.
33. Spunberg J, Chang C, Goldman M, et al. Quality of long-term survival following irradiation for intracranial tumors in children under the age of two. Int J Rad Oncol Biol Phys 1981; 7: 727-36.
34. Suc E, Kalifa C, Brauner R, et al. Brain tumours under the age of three. The price of survival. Acta Neurochir (Wien) 1990; 106: 93-8.
35. Tait D, Thorton-Jones H, Bloom H, et al. Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Pediatric Oncology (SIOP I). Eur J Cancer 1990; 26: 464-9.
36. Tartaglia R, Cole D, Heidemann R, et al. Chemosensitivity of central nervous system tumors to thiotepa and tepa. Proc Am Ass Cancer Res 1989; 30: 1833.
37. Tomita T, McLone D. Brain tumors during the first twenty-four months of life. Neurosurg 1985; 17: 913-9.
38. Van Eys, Cangir A, Coody D. MOPP regimen as primary chemotherapy for brain tumors in infants. J Neuro-Oncol 1985; 3: 237-43.
39. Vassal G, Gouyette A, Hartmann O, et al. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol 1989a; 24: 386-90.
40. Vassal G, Hartmann O, Habrand JL, et al. Enhanced cutaneous radiation effects following high-dose busulfan therapy. Cancer Chemother Pharmacol 1989b; 23: 117-8.
41. Vassal G, Hartmann O, Benhamou E. Busulfan and veno-occlusive disease of the liver. Ann Intern Med 1990a; 112: 881.
42. Vassal G, Debroussent G, Hartmann O, et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 1990b; 50: 6203-7.
43. Vassal G, Challine D, Koscielny S, et al. Chronopharmacology of high-dose busulfan in children Cancer Res 1993; 53: 1534-7.
44. Wacker P, Hartmann O, Benhamou E, et al. Varicella-zoster virus infection after autologous bone marrow transplantation in children. Bone Marrow Transplant 1989; 4: 191-4.
45. Wolff S, Herzig R, Fay J, et al. High dose thiotepa with autologous bone marrow transplantation: phase II studies. Semin Oncol 1990; 1: 2-6.